Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs

被引:172
作者
Sazani, P
Kang, SH
Maier, MA
Wei, CF
Dillman, J
Summerton, J
Manoharan, M
Kole, R
机构
[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA
[3] ISIS Pharmaceut Inc, Dept Med Chem, Carlsbad, CA 92008 USA
[4] GeneTools, Corvallis, OR 97339 USA
关键词
D O I
10.1093/nar/29.19.3965
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The antisense activity of oligomers with 2 ' -O-methyl (2 ' -O-Me) phosphorothioate, 2 ' -O-methoxyethyl (2 ' -O-MOE) phosphorothioate, morpholino and peptide nucleic acid (PNA) backbones was investigated using a splicing assay in which the modified oligonucleotides blocked aberrant and restored correct splicing of modified enhanced green fluorescent protein (EGFP) precursor to mRNA (pre-mRNA), generating properly translated EGFP. In this approach, antisense activity of each oligomer was directly proportional to up-regulation of the EGFP reporter. This provided a positive, quantitative readout for sequence-specific antisense effects of the oligomers in the nuclei of individual cells. Nuclear localization of fluorescent labeled oligomers confirmed validity of the functional assay. The results showed that the free uptake and the antisense efficacy of neutral morpholino derivatives and cationic PNA were much higher than that of negatively charged 2 ' -O-Me and 2 ' -O-MOE congeners. The effects of the PNA oligomers were observed to be dependent on the number Of L-lysine (Lys) residues at the C-terminus. The experiments suggest that the PNA containing Lys was taken up by a mechanism similar to that of cell-penetrating homeodomain proteins and that the Lys tail enhanced intracellular accumulation of PNA oligomer without affecting its ability to reach and hybridize to the target sequence.
引用
收藏
页码:3965 / 3974
页数:10
相关论文
共 38 条
[1]   Antisense therapeutics [J].
Agrawal, S ;
Zhao, QY .
CURRENT OPINION IN CHEMICAL BIOLOGY, 1998, 2 (04) :519-528
[2]   The delivery of antisense therapeutics [J].
Akhtar, S ;
Hughes, MD ;
Khan, A ;
Bibby, M ;
Hussain, M ;
Nawaz, Q ;
Double, J ;
Sayyed, P .
ADVANCED DRUG DELIVERY REVIEWS, 2000, 44 (01) :3-21
[3]  
Altmann KH, 1998, APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY, P73
[4]  
BENNETT CF, 1992, MOL PHARMACOL, V41, P1023
[5]  
CHRISTENSEN L, 1995, J PEPT SCI, V1, P175, DOI DOI 10.1002/PSC.310010304
[6]   Altered mRNA splicing and inhibition of human E-selectin expression by an antisense oligonucleotide in human umbilical vein endothelial cells [J].
Condon, TP ;
Bennett, CF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (48) :30398-30403
[7]  
Crooke ST, 2000, METHOD ENZYMOL, V313, P3
[8]  
CROOKE ST, 1998, NUCL ACID DRUG DEV, V8, pR7
[9]   Trojan peptides: the penetratin system for intracellular delivery [J].
Derossi, D ;
Chassaing, G ;
Prochiantz, A .
TRENDS IN CELL BIOLOGY, 1998, 8 (02) :84-87
[10]   Antisense comes of age [J].
Flanagan, WM .
CANCER AND METASTASIS REVIEWS, 1998, 17 (02) :169-176